Agalsidase beta vs Migalastat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Fabry Disease

Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline

Agalsidase beta · Fabrazyme

Marketed by Sanofi

Approved in Fabry Diseaseenzyme
Weak signal

NCT00837824 · Phase 2 · terminated

This study was randomized but not blinded, had no placebo control, and was terminated early after enrolling only a sixth of its planned patients; with just one clinical event recorded across both dose groups, it could not produce a meaningful comparison of Fabrazyme's effect on disease progression.

Reported efficacy

Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium (Baseline, Week 52, Week 156 and Week 260): Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). (unclear)

Result source: NCT00701415

Migalastat · Galafold

Marketed by Amicus Therapeutics and partners

Approved in Fabry Diseasesmall molecule
Partial signal

NCT00925301 · Phase 3 · completed

Participants were randomized and double-blinded to migalastat or placebo, with 34 and 33 participants assigned respectively. The primary endpoint was a kidney biopsy measure of GL-3 inclusions, a surrogate pathology measure rather than a direct clinical outcome; 13 of 32 migalastat-treated participants versus 9 of 32 placebo-treated participants achieved the target reduction, but the comparison was not statistically significant (p=0.2996).

Next expected readout: December 2026 · NCT04020055 (registry estimate)

Reported efficacy

Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants (missed)

Result source: NCT00925301

Results for Fabry Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Migalastat
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants NCT00925301 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Agalsidase beta

Time to CV Cerebrovascular Progression or Death 1.15 months1mg/kg Every 2 Weeks
time to event · months
No placebo or comparator arm
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 · converted to months from 35 days as posted
Available safety results

Agalsidase beta

Dropout rate
0%3mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
0%1mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
Discontinued due to AEs
—3mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
—1mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
Serious AEs
11.1%3mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
36.4%1mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
Most frequent reported AEs
3mg/kg Every 2 Weeks
oedema peripheral 33.3%
headache 22.2%
muscle spasms 22.2%
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
1mg/kg Every 2 Weeks
abdominal pain 18.2%
pyrexia 18.2%
transient ischaemic attack 18.2%
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Agalsidase beta's landscape · Migalastat's landscape